Obexelimab, a therapy Zenas Biopharma is developing for a range of autoimmune diseases, almost completely prevented the formation of new inflammatory lesions in adults with relapsing forms of multiple sclerosis […]
The post Obexelimab stops new MS brain lesions in clinical trial, data show appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com